Skip to Content
Merck
  • Split-face study using a 1,927-nm thulium fiber fractional laser to treat photoaging and melasma in Asian skin.

Split-face study using a 1,927-nm thulium fiber fractional laser to treat photoaging and melasma in Asian skin.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] (2013-03-08)
Hyung Min Lee, Sik Haw, Jae Kyung Kim, Sung Eun Chang, Mi Woo Lee
ABSTRACT

Although the 1,927-nm thulium fiber fractional laser is effective and safe for treating photoaging, clinical data regarding this modality remain limited. To investigate the efficacy and safety of the 1,927-nm thulium fiber fractional laser for treating photoaging and melasma in Asians. Twenty-five participants received three laser treatments (at 3-week intervals) on the half of the face with more-severe photoaging and melasma. Independent investigators evaluated clinical improvement 2 and 6 months after the final treatment. Improvement in melasma was evaluated using the Melasma Area and Severity Index. Subjective satisfaction rates were also evaluated. Adverse events were assessed, and pain was scored using a visual analog scale (VAS). Histologic changes were observed using immunohistochemical staining. Clinical improvement of photodamaged facial skin was remarkable on the treatment side. Most participants reported that their subjective satisfaction rate was greater than slight satisfaction. Downtime for healing required approximately 1 week. No severe adverse events occurred. Mean VAS score during treatment was 4.8. Collagen regeneration and melanin decrease were observed histologically. The 1,927-nm thulium fiber fractional laser is a safe, effective treatment for photoaging and melasma in Asians.